Signaling Pathway-Biomarker Coupling for Precision Therapy in Rheumatoid Arthritis: Mechanistic Insights,...

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a complex autoimmune disease with significant interindividual variability in treatment response.
• Current targeted therapies for RA often fall short of treat-to-target goals due to a lack of precise predictive tools.
• Heterogeneity in RA pathogenesis and a disconnect between research and clinical application hinder treatment efficacy.

Purpose of the Study:

• To establish a signaling pathway-biomarker-targeted therapy coupling paradigm for precision rheumatology in RA.
• To address unmet clinical needs by proposing a roadmap for pathway-guided individualized RA treatment.

Main Methods:

• Systematic literature review of core pathogenic signaling cascades (JAK/STAT, MAPK, PI3K-AKT/mTOR, SYK, Wnt, Notch) and their crosstalk in RA.
• Analysis of the direct coupling between pathway dysregulation and specific biomarkers.
• Evaluation of emerging therapeutic strategies and their potential for clinical translation.

Main Results:

• Identified direct mapping between aberrant signaling pathways and specific biomarkers in RA (e.g., IL-6/CRP for JAK/STAT, MMP-3 for MAPK).
• Argued that trial failures stem from treating RA as a single entity, not a spectrum of pathway-dominant endotypes.
• Highlighted emerging strategies like selective kinase inhibitors and novel drug delivery systems showing promise.

Conclusions:

• Bridging the gap between dysregulated signaling pathways and validated biomarkers is crucial for advancing precision medicine in RA.
• A pathway-guided approach is essential for overcoming RA heterogeneity and achieving personalized treatment.
• The proposed paradigm offers a roadmap for individualized RA treatment, improving clinical outcomes.